右佐匹克隆联合舍曲林对脑梗死后抑郁患者血清S100β的影响及其疗效研究

Effect of eszopiclone combined with sertraline on serum S100β and clinical efficacy in patients with depression after cerebral infarction

目的探讨右佐匹克隆联合舍曲林对脑梗死后抑郁患者血清中枢神经特异蛋白(central nerve specific protein,,S100β)及临床疗效的影响。方法收集收治的脑梗死后抑郁症患者58例,随机分为对照组和实验组,每组各29例,对照组患者给予舍曲林治疗,实验组在对照组基础上给予右佐匹克隆治疗,治疗结束后,对所有患者的血清S100β、脑源性神经营养因子(brain derived neurotrophic factor,BDNF)及临床疗效进行检测。结果治疗后,与对照组比较,实验组患者的血清S100β水平较低(P<0.05);实验组患者的血清BDNF水平较高(P<0.05);实验组患者的总有效率较高(P<0.05)。结论右佐匹克隆联合舍曲林能够显著降低脑梗死后抑郁症患者血清S100β蛋白水平,提高血清BDNF水平,提高治疗效果。

Objective To analyse the effect of eszopiclone combined with sertraline on serum S100β and clinical efficacy in patients with depression after cerebral infarction. Methods 58 patients who were diagnosed with depression after cerebral infarction were collected. All patients were randomly divided into experimental group and control group,29 cases in each group. Patients in the control group received sertraline treatment,patients in the experimental group were given eszopiclone treatment on the basis of control group,after the treatment,the serum levels of S100β,BDNF and clinical efficacy were detected in all patients. Results After treatment,compared with control group,the serum level of S100β was lower in the experimental group（ P〈0. 05）; the serum level of BDNF was higher in the experimental group（ P〈0. 05）; the total efficiency was higher in the experimental group（ P〈0. 05）. Conclusion The eszopiclone combined with sertraline can significantly reduce the serum level of S100β,and improve serum level of BDNF in patients with depression after cerebral infarction,improve the therapeutic effect.